Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

RPID vs DBVT vs IDXX vs ALKS vs NEOG

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
RPID
Rapid Micro Biosystems, Inc.

Medical - Devices

HealthcareNASDAQ • US
Market Cap$117M
5Y Perf.-88.1%
DBVT
DBV Technologies S.A.

Biotechnology

HealthcareNASDAQ • FR
Market Cap$1690.08T
5Y Perf.-62.1%
IDXX
IDEXX Laboratories, Inc.

Medical - Diagnostics & Research

HealthcareNASDAQ • US
Market Cap$44.49B
5Y Perf.-17.5%
ALKS
Alkermes plc

Biotechnology

HealthcareNASDAQ • IE
Market Cap$5.83B
5Y Perf.+35.3%
NEOG
Neogen Corporation

Medical - Diagnostics & Research

HealthcareNASDAQ • US
Market Cap$1.97B
5Y Perf.-79.2%

RPID vs DBVT vs IDXX vs ALKS vs NEOG — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
RPID logoRPID
DBVT logoDBVT
IDXX logoIDXX
ALKS logoALKS
NEOG logoNEOG
IndustryMedical - DevicesBiotechnologyMedical - Diagnostics & ResearchBiotechnologyMedical - Diagnostics & Research
Market Cap$117M$1690.08T$44.49B$5.83B$1.97B
Revenue (TTM)$31M$0.00$4.45B$1.56B$880M
Net Income (TTM)$-44M$-168M$1.10B$153M$-603M
Gross Margin18.4%62.1%65.4%38.0%
Operating Margin-148.8%31.6%12.3%-2.0%
Forward P/E38.3x24.5x25.3x
Total Debt$24M$22M$1.08B$70M$913M
Cash & Equiv.$20M$194M$180M$1.12B$129M

RPID vs DBVT vs IDXX vs ALKS vs NEOGLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

RPID
DBVT
IDXX
ALKS
NEOG
StockJul 21May 26Return
Rapid Micro Biosyst… (RPID)10011.9-88.1%
DBV Technologies S.… (DBVT)10037.9-62.1%
IDEXX Laboratories,… (IDXX)10082.5-17.5%
Alkermes plc (ALKS)100135.3+35.3%
Neogen Corporation (NEOG)10020.8-79.2%

Price return only. Dividends and distributions are not included.

Quick Verdict: RPID vs DBVT vs IDXX vs ALKS vs NEOG

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: IDXX and ALKS are tied at the top with 2 categories each (5-stock set) — the right choice depends on your priorities. Alkermes plc is the stronger pick specifically for valuation and capital efficiency and capital preservation and lower volatility. RPID and DBVT also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
RPID
Rapid Micro Biosystems, Inc.
The Growth Play

RPID ranks third and is worth considering specifically for growth exposure.

  • Rev growth 19.7%, EPS growth 2.8%, 3Y rev CAGR 25.2%
  • 19.7% revenue growth vs DBVT's -100.0%
Best for: growth exposure
DBVT
DBV Technologies S.A.
The Income Pick

DBVT is the clearest fit if your priority is income & stability.

  • Dividend streak 0 yrs, beta 1.26
  • +100.5% vs RPID's +7.3%
Best for: income & stability
IDXX
IDEXX Laboratories, Inc.
The Long-Run Compounder

IDXX has the current edge in this matchup, primarily because of its strength in long-term compounding.

  • 5.4% 10Y total return vs ALKS's -12.0%
  • 24.6% margin vs RPID's -145.1%
  • 32.6% ROA vs DBVT's -89.0%
Best for: long-term compounding
ALKS
Alkermes plc
The Defensive Pick

ALKS is the #2 pick in this set and the best alternative if sleep-well-at-night and defensive is your priority.

  • Lower volatility, beta 1.00, Low D/E 3.8%, current ratio 3.55x
  • Beta 1.00, current ratio 3.55x
  • Lower P/E (24.5x vs 25.3x)
  • Beta 1.00 vs RPID's 1.91, lower leverage
Best for: sleep-well-at-night and defensive
NEOG
Neogen Corporation
The Healthcare Pick

Among these 5 stocks, NEOG doesn't own a clear edge in any measured category.

Best for: healthcare exposure
See the full category breakdown
CategoryWinnerWhy
GrowthRPID logoRPID19.7% revenue growth vs DBVT's -100.0%
ValueALKS logoALKSLower P/E (24.5x vs 25.3x)
Quality / MarginsIDXX logoIDXX24.6% margin vs RPID's -145.1%
Stability / SafetyALKS logoALKSBeta 1.00 vs RPID's 1.91, lower leverage
DividendsTieNone of these 5 stocks pay a meaningful dividend
Momentum (1Y)DBVT logoDBVT+100.5% vs RPID's +7.3%
Efficiency (ROA)IDXX logoIDXX32.6% ROA vs DBVT's -89.0%

RPID vs DBVT vs IDXX vs ALKS vs NEOG — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

RPIDRapid Micro Biosystems, Inc.
FY 2025
Product
71.9%$26M
Service
28.1%$10M
DBVTDBV Technologies S.A.

Segment breakdown not available.

IDXXIDEXX Laboratories, Inc.
FY 2025
Product
59.0%$2.5B
Service
41.0%$1.8B
ALKSAlkermes plc
FY 2025
Vivitrol
39.8%$468M
Aristada And Aristada Initio
31.5%$370M
Manufactured Product And Royalty
24.8%$291M
Manufacturing Revenue
3.9%$46M
NEOGNeogen Corporation
FY 2025
Product
89.1%$797M
Service
10.9%$97M

RPID vs DBVT vs IDXX vs ALKS vs NEOG — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLALKSLAGGINGNEOG

Income & Cash Flow (Last 12 Months)

ALKS leads this category, winning 3 of 6 comparable metrics.

IDXX and DBVT operate at a comparable scale, with $4.4B and $0 in trailing revenue. IDXX is the more profitable business, keeping 24.6% of every revenue dollar as net income compared to RPID's -145.1%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricRPID logoRPIDRapid Micro Biosy…DBVT logoDBVTDBV Technologies …IDXX logoIDXXIDEXX Laboratorie…ALKS logoALKSAlkermes plcNEOG logoNEOGNeogen Corporation
RevenueTrailing 12 months$31M$0$4.4B$1.6B$880M
EBITDAEarnings before interest/tax-$42M-$112M$1.5B$212M$100M
Net IncomeAfter-tax profit-$44M-$168M$1.1B$153M-$603M
Free Cash FlowCash after capex-$39M-$151M$845M$392M$17M
Gross MarginGross profit ÷ Revenue+18.4%+62.1%+65.4%+38.0%
Operating MarginEBIT ÷ Revenue-148.8%+31.6%+12.3%-2.0%
Net MarginNet income ÷ Revenue-145.1%+24.6%+9.8%-68.5%
FCF MarginFCF ÷ Revenue-126.4%+19.0%+25.1%+2.0%
Rev. Growth (YoY)Latest quarter vs prior year+3.1%+14.3%+28.2%-2.8%
EPS Growth (YoY)Latest quarter vs prior year+3.8%+91.5%+16.6%-4.1%+96.5%
ALKS leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

Evenly matched — ALKS and NEOG each lead in 2 of 6 comparable metrics.

At 24.5x trailing earnings, ALKS trades at a 43% valuation discount to IDXX's 42.8x P/E. On an enterprise value basis, ALKS's 17.0x EV/EBITDA is more attractive than IDXX's 30.9x.

MetricRPID logoRPIDRapid Micro Biosy…DBVT logoDBVTDBV Technologies …IDXX logoIDXXIDEXX Laboratorie…ALKS logoALKSAlkermes plcNEOG logoNEOGNeogen Corporation
Market CapShares × price$117M$1690.08T$44.5B$5.8B$2.0B
Enterprise ValueMkt cap + debt − cash$121M$1690.08T$45.4B$4.8B$2.8B
Trailing P/EPrice ÷ TTM EPS-2.50x-0.75x42.82x24.47x-1.80x
Forward P/EPrice ÷ next-FY EPS est.38.29x25.31x
PEG RatioP/E ÷ EPS growth rate3.00x
EV / EBITDAEnterprise value multiple30.95x17.01x20.37x
Price / SalesMarket cap ÷ Revenue3.49x10.34x3.95x2.20x
Price / BookPrice ÷ Book value/share3.54x0.65x28.15x3.25x0.95x
Price / FCFMarket cap ÷ FCF42.23x12.14x
Evenly matched — ALKS and NEOG each lead in 2 of 6 comparable metrics.

Profitability & Efficiency

IDXX leads this category, winning 6 of 9 comparable metrics.

IDXX delivers a 70.9% return on equity — every $100 of shareholder capital generates $71 in annual profit, vs $-130 for DBVT. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to RPID's 0.72x. On the Piotroski fundamental quality scale (0–9), IDXX scores 7/9 vs NEOG's 3/9, reflecting strong financial health.

MetricRPID logoRPIDRapid Micro Biosy…DBVT logoDBVTDBV Technologies …IDXX logoIDXXIDEXX Laboratorie…ALKS logoALKSAlkermes plcNEOG logoNEOGNeogen Corporation
ROE (TTM)Return on equity-73.9%-130.2%+70.9%+8.8%-28.6%
ROA (TTM)Return on assets-51.6%-89.0%+32.6%+5.4%-17.9%
ROICReturn on invested capital-69.9%+42.5%+18.9%+0.2%
ROCEReturn on capital employed-69.2%-145.7%+61.4%+14.2%+0.2%
Piotroski ScoreFundamental quality 0–934773
Debt / EquityFinancial leverage0.72x0.13x0.67x0.04x0.44x
Net DebtTotal debt minus cash$4M-$172M$897M-$1.0B$784M
Cash & Equiv.Liquid assets$20M$194M$180M$1.1B$129M
Total DebtShort + long-term debt$24M$22M$1.1B$70M$913M
Interest CoverageEBIT ÷ Interest expense-107.47x-189.82x35.55x32.30x-8.33x
IDXX leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

RPID leads this category, winning 2 of 6 comparable metrics.

A $10,000 investment in ALKS five years ago would be worth $16,165 today (with dividends reinvested), compared to $1,229 for RPID. Over the past 12 months, DBVT leads with a +100.5% total return vs RPID's +7.3%. The 3-year compound annual growth rate (CAGR) favors RPID at 46.9% vs NEOG's -19.2% — a key indicator of consistent wealth creation.

MetricRPID logoRPIDRapid Micro Biosy…DBVT logoDBVTDBV Technologies …IDXX logoIDXXIDEXX Laboratorie…ALKS logoALKSAlkermes plcNEOG logoNEOGNeogen Corporation
YTD ReturnYear-to-date-16.2%+3.6%-16.4%+23.8%+29.3%
1-Year ReturnPast 12 months+7.3%+100.5%+14.3%+15.2%+51.1%
3-Year ReturnCumulative with dividends+216.9%+18.1%+15.4%+13.2%-47.3%
5-Year ReturnCumulative with dividends-87.7%-68.3%+6.6%+61.7%-80.4%
10-Year ReturnCumulative with dividends-87.7%-87.1%+542.3%-12.0%-50.9%
CAGR (3Y)Annualised 3-year return+46.9%+5.7%+4.9%+4.2%-19.2%
RPID leads this category, winning 2 of 6 comparable metrics.

Risk & Volatility

ALKS leads this category, winning 2 of 2 comparable metrics.

ALKS is the less volatile stock with a 1.00 beta — it tends to amplify market swings less than RPID's 1.91 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 95.6% from its 52-week high vs RPID's 53.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricRPID logoRPIDRapid Micro Biosy…DBVT logoDBVTDBV Technologies …IDXX logoIDXXIDEXX Laboratorie…ALKS logoALKSAlkermes plcNEOG logoNEOGNeogen Corporation
Beta (5Y)Sensitivity to S&P 5001.91x1.26x1.36x1.00x1.69x
52-Week HighHighest price in past year$4.94$26.18$769.98$36.60$11.43
52-Week LowLowest price in past year$2.01$7.53$485.41$25.17$4.53
% of 52W HighCurrent price vs 52-week peak+53.2%+75.3%+72.7%+95.6%+79.2%
RSI (14)Momentum oscillator 0–10053.947.449.260.547.4
Avg Volume (50D)Average daily shares traded205K252K535K2.2M2.5M
ALKS leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: RPID as "Buy", DBVT as "Buy", IDXX as "Buy", ALKS as "Buy", NEOG as "Hold". Consensus price targets imply 204.2% upside for RPID (target: $8) vs 21.5% for NEOG (target: $11).

MetricRPID logoRPIDRapid Micro Biosy…DBVT logoDBVTDBV Technologies …IDXX logoIDXXIDEXX Laboratorie…ALKS logoALKSAlkermes plcNEOG logoNEOGNeogen Corporation
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuyHold
Price TargetConsensus 12-month target$8.00$46.33$747.50$46.00$11.00
# AnalystsCovering analysts415222811
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises00
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap+0.1%0.0%+2.7%+0.5%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

ALKS leads in 2 of 6 categories (Income & Cash Flow, Risk & Volatility). IDXX leads in 1 (Profitability & Efficiency). 1 tied.

Best OverallAlkermes plc (ALKS)Leads 2 of 6 categories
Loading custom metrics...

RPID vs DBVT vs IDXX vs ALKS vs NEOG: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is RPID or DBVT or IDXX or ALKS or NEOG a better buy right now?

For growth investors, Rapid Micro Biosystems, Inc.

(RPID) is the stronger pick with 19. 7% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Alkermes plc (ALKS) offers the better valuation at 24. 5x trailing P/E, making it the more compelling value choice. Analysts rate Rapid Micro Biosystems, Inc. (RPID) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — RPID or DBVT or IDXX or ALKS or NEOG?

On trailing P/E, Alkermes plc (ALKS) is the cheapest at 24.

5x versus IDEXX Laboratories, Inc. at 42. 8x. On forward P/E, Neogen Corporation is actually cheaper at 25. 3x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — RPID or DBVT or IDXX or ALKS or NEOG?

Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +61.

7%, compared to -87. 7% for Rapid Micro Biosystems, Inc. (RPID). Over 10 years, the gap is even starker: IDXX returned +542. 3% versus RPID's -87. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — RPID or DBVT or IDXX or ALKS or NEOG?

By beta (market sensitivity over 5 years), Alkermes plc (ALKS) is the lower-risk stock at 1.

00β versus Rapid Micro Biosystems, Inc. 's 1. 91β — meaning RPID is approximately 92% more volatile than ALKS relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 72% for Rapid Micro Biosystems, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — RPID or DBVT or IDXX or ALKS or NEOG?

By revenue growth (latest reported year), Rapid Micro Biosystems, Inc.

(RPID) is pulling ahead at 19. 7% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: IDEXX Laboratories, Inc. grew EPS 22. 6% year-over-year, compared to -114. 6% for Neogen Corporation. Over a 3-year CAGR, RPID leads at 25. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — RPID or DBVT or IDXX or ALKS or NEOG?

IDEXX Laboratories, Inc.

(IDXX) is the more profitable company, earning 24. 6% net margin versus -140. 3% for Rapid Micro Biosystems, Inc. — meaning it keeps 24. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IDXX leads at 31. 6% versus -141. 1% for RPID. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is RPID or DBVT or IDXX or ALKS or NEOG more undervalued right now?

On forward earnings alone, Neogen Corporation (NEOG) trades at 25.

3x forward P/E versus 38. 3x for IDEXX Laboratories, Inc. — 13. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RPID: 204. 2% to $8. 00.

08

Which pays a better dividend — RPID or DBVT or IDXX or ALKS or NEOG?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is RPID or DBVT or IDXX or ALKS or NEOG better for a retirement portfolio?

For long-horizon retirement investors, IDEXX Laboratories, Inc.

(IDXX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+542. 3% 10Y return). Rapid Micro Biosystems, Inc. (RPID) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IDXX: +542. 3%, RPID: -87. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between RPID and DBVT and IDXX and ALKS and NEOG?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: RPID is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock; IDXX is a mid-cap quality compounder stock; ALKS is a small-cap quality compounder stock; NEOG is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

RPID

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

DBVT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

IDXX

Quality Mega-Cap Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 7%
  • Net Margin > 14%
Run This Screen
Stocks Like

ALKS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen
Stocks Like

NEOG

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 22%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.